UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The lancet oncology, ISSN 1470-2045, 2012, Volume 13, Issue 4, pp. 403 - 411
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Antibodies, Monoclonal, Humanized - adverse effects | Precursor Cell Lymphoblastic Leukemia-Lymphoma - epidemiology | United States | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Sialic Acid Binding Ig-like Lectin 2 - immunology | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Antibodies, Monoclonal, Humanized - administration & dosage | Enediynes - administration & dosage | Aminoglycosides - administration & dosage | Antibodies, Monoclonal - administration & dosage | Adolescent | Survival Analysis | Aged, 80 and over | Adult | Aged | Neoplasm Staging | Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology | Child | Viral antibodies | Oncology, Experimental | Stem cells | Monoclonal antibodies | Antibodies | Transplantation | Lymphomas | Research | Cancer | Relapse | Diseases | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 9, pp. 1099 - 1110
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Prognosis | Leukemia, Myeloid, Acute - pathology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols | Azacitidine - analogs & derivatives | Male | Dose-Response Relationship, Drug | Disease-Free Survival | Maximum Tolerated Dose | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Aged | Myelodysplastic Syndromes - pathology | Neoplasm Staging | Myelodysplastic Syndromes - drug therapy | Azacitidine - administration & dosage | Epigenetic inheritance | Safety and security measures | Molecular biology | Methylation | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 10, pp. 1090 - 1099
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Prognosis | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Antibodies, Monoclonal - therapeutic use | Male | Neoplasm Recurrence, Local - mortality | Patient Selection | Dose-Response Relationship, Drug | Aged, 80 and over | Adult | Female | Pyrazoles - adverse effects | Drug Administration Schedule | Administration, Oral | Pyrimidines - administration & dosage | Kaplan-Meier Estimate | Rituximab | Survival Rate | Treatment Outcome | Neoplasm Recurrence, Local - diagnosis | Disease-Free Survival | Maximum Tolerated Dose | Pyrazoles - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Antibodies, Monoclonal, Murine-Derived - adverse effects | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Leukemia, Lymphocytic, Chronic, B-Cell - diagnosis | Antimitotic agents | Monoclonal antibodies | Safety and security measures | Antineoplastic agents | Index Medicus
Journal Article
Mayo Clinic proceedings, ISSN 0025-6196, 2015, Volume 90, Issue 10, pp. 1440 - 1454
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Diagnosis, Differential | Prognosis | Protein Kinase Inhibitors - classification | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - physiopathology | Humans | Clinical Protocols | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Patient Outcome Assessment | Disease Progression | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis | Protein Kinase Inhibitors - pharmacology | Philadelphia Chromosome | Index Medicus | Abridged Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 07/2015, Volume 121, Issue 13, pp. 2106 - 2107
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 57 - 66
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Recurrence | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - pathology | Age Factors | United States | Humans | Middle Aged | Salvage Therapy | Drug Resistance, Neoplasm | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Young Adult | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Time Factors | Antineoplastic Agents - adverse effects | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - mortality | Antibodies, Bispecific - administration & dosage | Adult | Female | Drug Administration Schedule | Europe | Kaplan-Meier Estimate | Hematopoietic Stem Cell Transplantation | Treatment Outcome | Remission Induction | Antibodies, Bispecific - therapeutic use | Disease-Free Survival | Antibodies, Bispecific - adverse effects | Adolescent | Intention to Treat Analysis | Aged | Infusions, Intravenous | T cells | Adults | Safety and security measures | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 15, pp. 1547 - 1555
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Dexamethasone - administration & dosage | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Imidazoles - administration & dosage | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Antineoplastic Agents - administration & dosage | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Disease-Free Survival | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyridazines - administration & dosage | Vincristine - administration & dosage | Adult | Female | Aged | Philadelphia Chromosome | Doxorubicin - administration & dosage | Genetic research | Chemotherapy | Cancer | Heart | Tyrosine | Care and treatment | Corticosteroids | Cardiac patients | Bilirubin | Index Medicus
Journal Article
Mayo Clinic proceedings, ISSN 0025-6196, 2015, Volume 90, Issue 4, pp. 500 - 504
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Drug Costs | Health Care Sector - economics | United States | Drug Industry - economics | Humans | Antineoplastic Agents - economics | Antimitotic agents | Prices and rates | Antineoplastic agents | Analysis | Medical care, Cost of | Index Medicus | Abridged Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 07/2015, Volume 121, Issue 13, pp. 2106 - 2107
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 1, pp. 100 - 111
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Prognosis | Follow-Up Studies | Humans | Leukemia, Myeloid, Acute - epidemiology | Middle Aged | Male | Leukemia, Myeloid, Acute - etiology | Case-Control Studies | Incidence | Neoplasms - therapy | Adult | Female | High-Throughput Nucleotide Sequencing - methods | Texas - epidemiology | Risk Factors | Hematopoiesis - genetics | Survival Rate | Combined Modality Therapy - adverse effects | Mutation - genetics | Myelodysplastic Syndromes - epidemiology | Clone Cells - metabolism | Myelodysplastic Syndromes - etiology | Neoplasms, Second Primary - diagnosis | Neoplasms, Second Primary - epidemiology | Neoplasms, Second Primary - etiology | Myelodysplastic Syndromes - diagnosis | Clone Cells - pathology | Leukemia, Myeloid, Acute - diagnosis | Aged | Biomarkers, Tumor - genetics | Neoplasm Staging | Neoplasms - pathology | Lymphomas | Epidemiology | Leukemia | Risk factors | Tumors | Index Medicus
Journal Article